gp120Theglycoproteinthat wastargeted by theVAX 003 and004 trialsbNAbThe name of theapproach ofusing antibodiesthat recognizinga wide range ofHIV-1 strains3How manypatients dieddue to non-relapsecauses?4injections/halfyearDosagefor RV144trialCOVIDmRNA-basedvaccinetechnology wasused to create asuccessful vaccinefor this disease:MosaicvaccinedesignNew vaccineapproach thathopes to maximizeT-cell epitopes anduses artificiallyconstructedantigensSTEPThe name of theclinical trial that tookplace around thesame time as theSTEP trial andattempted to induceCD8+ T cell response(terminated now)mRNAbasedvaccinetechnologyNew vaccineapproach that usesRNA to produce viralprotein to instigate animmune response.Method was used toproduce COVIDvaccineAPPROACHThe name of theclinical trial for theMosaic VaccineDesign that showedsome success forvectors Ad26 andMVA15%Percentage ofHIV transmittednon-sexually(needles,blood, motherto child)HVTN702Clinical trial built onRV144, specifyingto clades in SouthAfrica andattempted toincrease efficacy ofRV144RV144The name of theclinical trial that isnow consideredthe milestoneevent in HIVvaccine researchRelapse ofmalignancy(cancer)the primary causeof treatment failurein the AllogeneicHematopoietic CellTransplant studyMF59AdjuvantThe adjuvantthat wasused in theHVTN702trialARTThe name ofthe drug thatsuppressedHIV toundetectableamountsPrimeBoostStrategiesVaccine approachused by RV144 trialthat involved theuse of a viralvector+recombinantproteinIAVIG001Name of the phase1 trial of the mRNA-based vaccine, wasfound to activategermline to producethe correct bNAbsHepatitisBNeutralizingantibodies wereused to createa successfulvaccine for thisdisease:AMPTrialName of thetrial thatused VRC01bNAbAlumadjuvantThe adjuvantthat wasused in theRV144 trialHIV-CORE004Name of thephase 1 trialfor theHIVconsvvaccine100%percentage ofpatients hadundetectable HIVDNA in their bloodcells with completechimerism85%Percentageof HIVtransmittedsexuallyNeutralizingantibodiesApproach forHIV vaccine thattargeted gp120and gp160 andworked for HepB vaccineCD8+T-cellName of cell thatwas found to havea significantdecrease after anHIV infection,response targetedin STEP trial24.4monthsmedianfollow-uptime forsurvivors inthis studyHIVconsvVaccineNew vaccineapproach thathopes to induce Tcell response.Notable trialsinclude HIV-CORE00469%Number of HIV+patients achievedcompletechimerism at 6months post-transplantPrEPThe name ofthe currentHIVpreventativedruggp120Theglycoproteinthat wastargeted by theVAX 003 and004 trialsbNAbThe name of theapproach ofusing antibodiesthat recognizinga wide range ofHIV-1 strains3How manypatients dieddue to non-relapsecauses?4injections/halfyearDosagefor RV144trialCOVIDmRNA-basedvaccinetechnology wasused to create asuccessful vaccinefor this disease:MosaicvaccinedesignNew vaccineapproach thathopes to maximizeT-cell epitopes anduses artificiallyconstructedantigensSTEPThe name of theclinical trial that tookplace around thesame time as theSTEP trial andattempted to induceCD8+ T cell response(terminated now)mRNAbasedvaccinetechnologyNew vaccineapproach that usesRNA to produce viralprotein to instigate animmune response.Method was used toproduce COVIDvaccineAPPROACHThe name of theclinical trial for theMosaic VaccineDesign that showedsome success forvectors Ad26 andMVA15%Percentage ofHIV transmittednon-sexually(needles,blood, motherto child)HVTN702Clinical trial built onRV144, specifyingto clades in SouthAfrica andattempted toincrease efficacy ofRV144RV144The name of theclinical trial that isnow consideredthe milestoneevent in HIVvaccine researchRelapse ofmalignancy(cancer)the primary causeof treatment failurein the AllogeneicHematopoietic CellTransplant studyMF59AdjuvantThe adjuvantthat wasused in theHVTN702trialARTThe name ofthe drug thatsuppressedHIV toundetectableamountsPrimeBoostStrategiesVaccine approachused by RV144 trialthat involved theuse of a viralvector+recombinantproteinIAVIG001Name of the phase1 trial of the mRNA-based vaccine, wasfound to activategermline to producethe correct bNAbsHepatitisBNeutralizingantibodies wereused to createa successfulvaccine for thisdisease:AMPTrialName of thetrial thatused VRC01bNAbAlumadjuvantThe adjuvantthat wasused in theRV144 trialHIV-CORE004Name of thephase 1 trialfor theHIVconsvvaccine100%percentage ofpatients hadundetectable HIVDNA in their bloodcells with completechimerism85%Percentageof HIVtransmittedsexuallyNeutralizingantibodiesApproach forHIV vaccine thattargeted gp120and gp160 andworked for HepB vaccineCD8+T-cellName of cell thatwas found to havea significantdecrease after anHIV infection,response targetedin STEP trial24.4monthsmedianfollow-uptime forsurvivors inthis studyHIVconsvVaccineNew vaccineapproach thathopes to induce Tcell response.Notable trialsinclude HIV-CORE00469%Number of HIV+patients achievedcompletechimerism at 6months post-transplantPrEPThe name ofthe currentHIVpreventativedrug

Journal Club - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
  1. The glycoprotein that was targeted by the VAX 003 and 004 trials
    gp120
  2. The name of the approach of using antibodies that recognizing a wide range of HIV-1 strains
    bNAb
  3. How many patients died due to non-relapse causes?
    3
  4. Dosage for RV144 trial
    4 injections/half year
  5. mRNA-based vaccine technology was used to create a successful vaccine for this disease:
    COVID
  6. New vaccine approach that hopes to maximize T-cell epitopes and uses artificially constructed antigens
    Mosaic vaccine design
  7. The name of the clinical trial that took place around the same time as the STEP trial and attempted to induce CD8+ T cell response (terminated now)
    STEP
  8. New vaccine approach that uses RNA to produce viral protein to instigate an immune response. Method was used to produce COVID vaccine
    mRNA based vaccine technology
  9. The name of the clinical trial for the Mosaic Vaccine Design that showed some success for vectors Ad26 and MVA
    APPROACH
  10. Percentage of HIV transmitted non-sexually (needles, blood, mother to child)
    15%
  11. Clinical trial built on RV144, specifying to clades in South Africa and attempted to increase efficacy of RV144
    HVTN 702
  12. The name of the clinical trial that is now considered the milestone event in HIV vaccine research
    RV144
  13. the primary cause of treatment failure in the Allogeneic Hematopoietic Cell Transplant study
    Relapse of malignancy (cancer)
  14. The adjuvant that was used in the HVTN702 trial
    MF59 Adjuvant
  15. The name of the drug that suppressed HIV to undetectable amounts
    ART
  16. Vaccine approach used by RV144 trial that involved the use of a viral vector+recombinant protein
    Prime Boost Strategies
  17. Name of the phase 1 trial of the mRNA-based vaccine, was found to activate germline to produce the correct bNAbs
    IAVI G001
  18. Neutralizing antibodies were used to create a successful vaccine for this disease:
    Hepatitis B
  19. Name of the trial that used VRC01 bNAb
    AMP Trial
  20. The adjuvant that was used in the RV144 trial
    Alum adjuvant
  21. Name of the phase 1 trial for the HIVconsv vaccine
    HIV-CORE 004
  22. percentage of patients had undetectable HIV DNA in their blood cells with complete chimerism
    100%
  23. Percentage of HIV transmitted sexually
    85%
  24. Approach for HIV vaccine that targeted gp120 and gp160 and worked for Hep B vaccine
    Neutralizing antibodies
  25. Name of cell that was found to have a significant decrease after an HIV infection, response targeted in STEP trial
    CD8+ T-cell
  26. median follow-up time for survivors in this study
    24.4 months
  27. New vaccine approach that hopes to induce T cell response. Notable trials include HIV-CORE 004
    HIVconsv Vaccine
  28. Number of HIV+ patients achieved complete chimerism at 6 months post-transplant
    69%
  29. The name of the current HIV preventative drug
    PrEP